Evidence map›Paper›PMID 40658307›Full record

ArticleInternational journal of clinical oncology2025

Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study.

Norifumi Iseda, Shinji Itoh, Mizuki Ninomiya, Hiroto Kayashima, Takashi Motomura, Takuma Izumi, Takeo Toshima, Shohei Yoshiya, Yo-Ichi Yamashita, Kengo Fukuzawa and 13 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Norifumi IsedaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Shinji ItohDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. itoh.shinji.453@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0003-0382-2520
Mizuki NinomiyaDepartment of Surgery, ASO Iizuka Hospital, Fukuoka, 820-8505, Japan.
Hiroto KayashimaDepartment of Surgery, ASO Iizuka Hospital, Fukuoka, 820-8505, Japan.
Takashi MotomuraDepartment of Surgery, ASO Iizuka Hospital, Fukuoka, 820-8505, Japan.
Takuma IzumiDepartment of Surgery, ASO Iizuka Hospital, Fukuoka, 820-8505, Japan.
Takeo ToshimaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Shohei YoshiyaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Yo-Ichi YamashitaDepartment of Surgery, Japanese Oita Red Cross Hospital, Oita, 870-0033, Japan.
Kengo FukuzawaDepartment of Surgery, Japanese Oita Red Cross Hospital, Oita, 870-0033, Japan.
Toru UtsunomiyaDepartment of Surgery, Oita Prefectural Hospital, Oita, 870-8511, Japan.
Shoichi InokuchiDepartment of Surgery, Oita Prefectural Hospital, Oita, 870-8511, Japan.
Takashi MaedaDepartment of Surgery, Japanese Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, 730-8619, Japan.
Eiji TsujitaDepartment of Surgery, Japanese Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, 730-8619, Japan.
Kazutoyo MoritaDepartment of Surgery, Fukuoka City Hospital, Fukuoka, 812-0046, Japan.
Hidefumi HigashiDepartment of Surgery, Fukuoka City Hospital, Fukuoka, 812-0046, Japan.
Keishi SugimachiDepartment of Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan.
Takahiro TominoDepartment of Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan.
Ryosuke MinagawaDepartment of Surgery, Japanese Red Cross Matsuyama Hospital, Matsuyama, 790-8524, Japan.
Koichi KimuraDepartment of Surgery, Japanese Red Cross Matsuyama Hospital, Matsuyama, 790-8524, Japan.
Hideaki UchiyamaDepartment of Surgery, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka, 811-3195, Japan.
Noboru HaradaDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, 810-0001, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

Kaken Pharmaceutical JP-23K08133
6 · The paper itself

Abstract

backgroundThe oncological criteria of resectability for HCC were reported by the Japanese Expert Consensus 2023. The relationship between classification at recurrence and prognosis is unclear in cases with surgical resection in the initial treatment. Factors that predict recurrence patterns are also unknown.

methodsData were analyzed retrospectively from 937 patients who underwent hepatic resection for primary HCC at 10 facilities. Kaplan-Meier analyses of overall survival (OS) and recurrence-free survival (RFS) after hepatic resection defined according to resectability classification, resectable (R), borderline resectable (BR) 1, and BR2, were performed. In patients who underwent curative resection for R-HCC, we examined the classification and prognosis at the time of recurrence, as well as the factors associated with BR1 or BR2 recurrence.

resultsRFS and OS rates were significantly better in the R group than in the BR1 and BR2 groups (P < 0.01). Prognosis was worse in patients whose initial HCC was resected with R and whose recurrence was BR1 or BR2 (P < 0.01). Male sex, α-fetoprotein > 12 ng/dL, Des-γ-carboxy prothrombin > 150 mAU/mL, tumor size > 5 cm, poor differentiation, and microscopic vascular invasion were predictors of BR1 or BR2 recurrence within 2 years after curative resection for R-HCC. We developed a scoring system based on these six factors, which stratified not only prognosis but also recurrence pattern.

conclusionsOur results extend this framework by demonstrating the prognostic significance at the time of recurrence and provide factors to predict high-risk recurrence.

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesHepatocellular carcinomaMulti-center studyOncologic resectability classification

Identifiers

PMID40658307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.